Compare Crispr Therapeutics AG (CRSP) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Nano Dimension Ltd - ADR — how do they compare? Crispr Therapeutics AG trades at $53.55 (market cap $4.88B), while Nano Dimension Ltd - ADR trades at $1.55 (market cap $328.52M). The key difference: Crispr Therapeutics AG is far larger — about 14.9× Nano Dimension Ltd - ADR's market cap, and Crispr Therapeutics AG is more actively traded (2,861,747 versus 1,160,945). Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Nano Dimension Ltd - ADR for 43 Days on average.
| CRSP | NNDM | |
|---|---|---|
Market Cap | $4.88B | $328.52M |
Volume | 2,861,747 | 1,160,945 |
Sector | Health | Technology |
52-Week High | $74.92 | $2.14 |
52-Week Low | $44.34 | $1.21 |
Typical Hold Time | 77 Days | 43 Days |
Enterprise Value | $3.30B | -$76.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
Nano Dimension (NNDM) trades at $1.55 with no recent price movement, reflecting a bearish technical signal. The company shows revenue growth from $102M in 2025 to $121M in 2026 but continues to report significant net losses, with a -135.18% net income margin. Recent strategic actions include cost-saving initiatives and leadership changes, with the sale of MarkForged expected to close in late 2026. Cash flow remains volatile, with 2025 showing a net cash outflow of $112M.
The outlook remains challenging due to persistent losses and cash burn, though revenue growth and asset sales provide some stability. Investment opportunities exist if cost reductions translate to profitability, but risks include ongoing operational losses and competitive pressures in the industrial sector. The stock's low valuation multiples may attract value investors, but sustained profitability is needed for long-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
